PDCD1 and neoplasm: We show that, in terms of the animal model, engrafted human HSCs displayed self-renewal and multilineage differentiation capacities and that anti-PD-1 antibody therapy may result, as observed in clinical studies, in varying effects, with some PDXs responding positively to the treatment (i.e., significant reduction in tumor growth and increased survival), whereas others show no signs of improvement.